Every clinical microbiologist eventually encounters a case that doesn’t fit. 

The Gram stain is unrevealing. Routine cultures remain negative. The patient’s illness progresses despite exhaustive testing. Most of these mysteries ultimately prove to be uncommon presentations of familiar diseases. Occasionally, however, they reveal something medicine has never seen before. 

That was the challenge confronting investigators in Philadelphia during the summer of 1976. 

More than 2,000 members of the American Legion had gathered at the Bellevue-Stratford Hotel to celebrate the nation’s bicentennial. Within days, attendees began developing severe pneumonia. Hospitals are filled with critically ill patients. Thirty-four people ultimately died. Clinicians searched for familiar pathogens. Laboratories cultured specimens, investigated viral etiologies, and considered environmental toxins. Nothing explained the outbreak. 

Months later, investigators at the Centers for Disease Control and Prevention isolated a previously unknown bacterium from stored lung tissue. The organism—later named Legionella pneumophila—not only solved one of the most perplexing outbreak investigations in modern medicine but fundamentally changed clinical microbiology. 

Fifty years later, the Philadelphia outbreak remains more than a historical milestone. It is a reminder that the greatest advances in our profession often begin when laboratory professionals are willing to question their assumptions. 

Every limitation became a discovery  

Looking back with today’s diagnostic capabilities, it is tempting to believe the organism should have been identified quickly. 

It was anything but straightforward. 

Routine bacteriologic media failed because Legionella required buffered charcoal yeast extract (BCYE) agar, a medium that was not part of routine clinical laboratory practice. What initially appeared to be a failure of microbiology instead became a lesson in its limitations: laboratories can identify only what they are equipped to recover. 

The ecological niche of the organism was equally unexpected. Investigators eventually traced the source to man-made water systems, forever changing how microbiologists, engineers, infection preventionists, and public health officials approached environmental surveillance. Cooling towers, potable water systems, and healthcare water management became integral to preventing disease rather than simply responding to it. 

Another, often overlooked, challenge involved understanding pathogenesis. Traditional laboratory animal models provided only limited insight into the disease, slowing efforts to characterize virulence and host interactions. Progress accelerated as investigators identified more suitable experimental systems, including guinea pigs, and later recognized that Legionella had evolved not primarily to infect humans but to parasitize free-living amoebae in aquatic environments. The same intracellular mechanisms that allowed survival within environmental protozoa proved remarkably effective within human alveolar macrophages. 

Few discoveries have so elegantly linked environmental microbiology, microbial evolution, and human disease. 

Each obstacle ultimately became a scientific breakthrough. Every limitation expanded the discipline itself. 

Fifty years of transformation  

The laboratory that investigated the Philadelphia outbreak would be almost unrecognizable today. 

Culture remains indispensable, but it is now complemented by urinary antigen testing, polymerase chain reaction, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, whole-genome sequencing, and increasingly, metagenomic next-generation sequencing. Molecular epidemiology now allows laboratories to connect clinical isolates with environmental reservoirs in ways unimaginable in 1976. 

The evolution extends beyond diagnostics. 

Many questions that once depended almost exclusively on animal models can now be explored through human organoids, air-liquid interface respiratory cultures, organ-on-chip platforms, advanced cellular models, single-cell sequencing, and increasingly sophisticated computational approaches. While animal models remain indispensable in many areas of infectious disease research, today’s experimental toolkit provides opportunities to investigate host-pathogen interactions with unprecedented precision. 

Every generation of microbiologists has been constrained by the tools available to them. Every generation has also expanded those boundaries. 

The next Legionella 

The Philadelphia outbreak reminds us that emerging pathogens rarely announce themselves as new diseases. 

Instead, they appear as unexplained pneumonias, culture-negative infections, unusual epidemiologic clusters, or laboratory results that simply do not fit. 

Today’s clinical microbiologists possess technologies that investigators in 1976 could scarcely imagine. Artificial intelligence is beginning to assist with diagnostic interpretation and outbreak detection. Metagenomic sequencing identifies organisms that evade conventional culture. Whole genome sequencing links isolate across continents in near real time. Environmental genomics is redefining our understanding of microbial reservoirs. 

These advances are extraordinary. 

But they do not eliminate uncertainty. 

Every diagnostic platform has blind spots. Every testing algorithm reflects assumptions about what organisms are likely to be present. Every generation risks believing its technology has finally conquered the unknown. 

History suggests otherwise. 

Teaching curiosity 

When I discuss Legionnaires’ disease with pathology residents, I typically begin with urinary antigen testing or the microbiologic characteristics of Legionella. Before stopping, however I ask them to imagine practicing clinical microbiology in 1976. 

What would they have done with negative cultures? 

Would they have continued searching after familiar explanations failed? 

What assumptions would they have questioned? 

The discussion inevitably shifts from history to the present. 

What assumptions are we making today? Which organisms remain invisible because we lack the appropriate methods to detect them? Which diseases will future microbiologists wonder how we could have missed? 

These conversations have become an important part of how I teach microbiology because they emphasize something that no technology can replace: scientific curiosity. Residents certainly need to master molecular diagnostics, susceptibility testing, and laboratory stewardship. They also need to appreciate that progress in microbiology has always depended upon individuals willing to challenge prevailing assumptions and pursue unexpected findings. 

The history of Legionnaires’ disease reminds us that discovery is not simply the product of better instruments. It begins with asking better questions. 

Looking forward 

Fifty years after the discovery of Legionella pneumophila, perhaps its greatest legacy is not the organism itself. 

Rather, it is the reminder that clinical microbiology is defined as much by curiosity as by technology. 

The investigators who solved the Philadelphia outbreak were not limited by a lack of intelligence or determination. They were limited by the tools of their era. Yet they transformed medicine because they refused to accept that the absence of an answer meant the absence of one. 

Today, our laboratories are equipped with technologies that those investigators could scarcely have imagined. Artificial intelligence, metagenomics, organ-on-chip systems, and genomic epidemiology continue to reshape how we diagnose infectious diseases and investigate outbreaks. These innovations will undoubtedly lead to discoveries that redefine our specialty over the next fifty years. 

The challenge for today’s clinical microbiologists is not whether our tools are more powerful—they unquestionably are. It is whether we are asking the kinds of questions that allow discovery to happen. 

Somewhere today, another unexplained outbreak is beginning. 

When it does, the next great advance in clinical microbiology will begin not with a machine, but with someone in a laboratory willing to ask the same question investigators asked in Philadelphia fifty years ago. 

In September 2025, President Donald Trump issued a presidential proclamation increasing the fee for new H-1B visas—for skilled foreign professionals to have temporary employment—to $100,000, an unprecedented increase. This increase made sponsoring international pathologists and laboratory professionals prohibitively expensive for many healthcare employers.  

Although a federal court recently blocked the proposed fee, the Trump Administration has appealed the ruling and consequently the court has stayed its decision pending the appeal. For many pathology and laboratory leaders, the new policy exposed just how fragile an already strained workforce has become, and it may also have discouraged more international professionals from pursuing employment opportunities in the U.S.  

The American Society for Clinical Pathology (ASCP), the ASCP Board of Certification (BOC), and members of the Medical and Public Health Laboratory Workforce Coalition (MPHLWC) joined a bipartisan congressional effort urging that healthcare professionals be exempted from the proposed fee. 

The fee debacle has laid bare that immigration policy has a direct impact on whether patients receive timely laboratory testing and the effective operation of healthcare systems.  

Why rural laboratories are especially vulnerable  

When the fee was first announced, it alarmed Rex F. Famitangco, MS, MASCP, MLS(ASCP)CM, QLCCM, LPH-C, IFBA PC, RBP(ABSA), Director of Laboratory Services at Morrill County Community Hospital, in Bridgeport, Nebraska, where approximately 40 percent of his workforce is employed under H-1B. Rural laboratories are particularly vulnerable because vacancies can be higher in rural and underserved areas, and remain open for months. Thus, internationally trained professionals, vital to maintaining laboratory services and filling critical workforce needs, can often find jobs in these locations. 

“These professional workers are not simply temporary workers,” Mr. Famitangco says, “they are trusted colleagues, community members, and essential members of our healthcare team. Without them, maintaining services such as blood banking, microbiology, chemistry, and twenty-four-seven laboratory operations would be extremely difficult.”  

Not only would replacing even five of Mr. Famitangco’s employees have cost his hospital a prohibitive half a million dollars, but it would also have had a negative impact on patient care. “It would delay testing. It could possibly reduce our services, [create] longer turnaround times and workforce instability," he says.  

One visa, one career, decades of service 

For Mr. Famitangco, the issue is deeply personal. He came to the United States 23 years ago on an H-1B visa. "I was a temporary solution, but I became a permanent solution." He stresses how important H-1B workers are to the laboratory. 

He feels his story “reflects on the original purpose of Congress envisioning what an H-1B program should look like” which is “a highly trained professional filling a critical workforce need, serving rural underserved communities, and ultimately becoming a long-term solution here in the United States, which I call my home."  

While under H-1B sponsorship, Mr. Famitangco earned an ASCP certification, his credentials, and advanced through leadership. “Now, today, I still continue to serve as the director of laboratory services in a critical access hospital in rural Nebraska,” he says. 

Why rural laboratories face unique workforce challenges 

Laboratory workforce shortages hit rural healthcare systems especially hard. "A lot of the folks that come here on immigrant work visas tend to work in rural and underserved areas [which] tend to have the most acute shortages,” explains Matthew Schulze, ASCP’s Senior Director for the Center for Public Policy. 

Unlike larger health systems, rural laboratories often operate with smaller staff, broader individual responsibilities, and far fewer recruitment options.  

Reduction in staff or delays in testing or diagnosis could significantly impact people’s care. Mr. Famitangco explains that the patients who come to their emergency rooms “are often experiencing the worst-case scenario."  

ASCP's advocacy extended beyond one court case 

The ASCP and the ASCP BOC did not wait to see what would happen regarding the proposed fee, Mr. Schulze says. "When Trump proposed the H-1B visa fee, we pretty quickly managed to get a letter over to the U.S. Department of Homeland Security... seeking an exemption for the laboratory and pathology workforce."  

ASCP also rallied the Medical and Public Health Laboratory Workforce Coalition "to engage the whole laboratory community on this issue," Mr. Schulze explains.  

Meanwhile, DHS finalized another rule that abandons the current H-1B visa lottery program for a less egalitarian income tiering approach. “[This] basically means that the more money you make, the more likely you are to get a visa,” Mr. Schulze explains.  

Though challenges persist, Mr. Famitangco appreciates the way that ASCP “continues to be a strong advocate to the workforce... the patient is our center. That's why we're here." 

The H-1B proposal highlighted a bigger workforce problem 

Because of the pending appeal, the fee policy remains in effect, with fees still being collected until the appeals process is exhausted, Mr. Schulze says. However, regardless of the fee’s fate, significant workforce challenges remain. 

Mr. Schulze points out, "We've got this issue where we don't spend money to train the domestic workforce, and we aren't really encouraging international talent. So, the result is worsening personnel shortages." 

Making it harder for international talent to come work here will not help, he says, and losing existing professionals will only make things worse, because “the amount of time that it takes to replace a position can take more than a year for most departments." And vacant positions in a healthcare system “mean the workload on the remaining staff can get more intense." 

Given the workforce shortages in the laboratory, Mr. Schulze says, “We need to address that before it gets worse, and immigration is one of those ways that we can deal with it.” 

Not only can bringing in foreign talent keep laboratories and healthcare systems running better, “it can help mitigate other challenges,” he says. “A vacant position could mean the lab has to turn away business. We're doing what we can to make sure that this is a tool that employers can use at their choice. It's not being forced on them,” he says.  

Building the workforce for the long term 

Mr. Famitangco didn’t wait to let the workforce shortage in his rural Nebraska area become an even greater problem. He established a phlebotomy program in 2009 and a medical laboratory technician associate’s degree program in 2017 at Western Nebraska Community College. He sees those efforts as both giving back to the community and providing opportunities.  

"For us to have a sustainable workforce, my thinking was let’s build it in our own backyard,” he explains.  

He’s seen that effort continue to bear fruit. “Some of the graduates are now my employees too,” he says. 

His hope is that “people see more than a visa category because every H-1B professional is a person who left their country to contribute, who chose to serve.” He considers himself just one example “of a single investment in a healthcare professional that can positively impact thousands of patients, students, colleagues and communities over time.”  

One of the most common ways to enter the laboratory is through a family member, where interest is often sparked through a demonstration of the field in person. For the Dimit/Snider family, that spark began with an uncle who worked in a hospital laboratory and grew into a family legacy spanning decades of service in laboratory medicine.  

Hooked at the first look through a microscope  

As a child, Lois Snider, BSMT, ASCP, age 73, now a retired point-of-care coordinator, wanted to become a nurse “to help people.” However, as a teen, a laboratory tour by her uncle, a chief technician in the laboratory at Indiana Hospital, changed the trajectory of her career before it began. 

"When he took me up there through his lab, it got me hooked," she says. She remembers looking through the microscope at blood on a slide and feeling awed. Her interest in biology merged well with laboratory work. 

Lois was far from the last one in her family to enter a laboratory profession. She would next influence her brother Roger. 

A career detour  

Roger Dimit, BSMT, ASCP, age 69, a retired medical technologist, also experienced a change to his original plan to become a physician’s assistant after graduating high school. When he found himself competing with Vietnam veteran corpsmen who already had medical training, he reflected on his sister and uncle’s careers in laboratory medicine and pivoted, finding his way into medical technology.  

Driven to help others, like his sister, he also had a sense that the field was a solid career choice “because I would always have a job at it. It wouldn't be something I would be getting laid off from." 

Growing up in the laboratory 

Unlike his father and aunt, Steven Dimit, MLS(ASCP)^CM, age 40, a medical laboratory scientist, did not need to discover laboratory medicine as a teenager or young adult—he essentially grew up in it. The hospital where his parents worked doubled as an unofficial daycare, giving him a front-row seat to the laboratory long before he considered it as a career. His mother worked as a nurse at the same hospital. “My dad worked day light and my mom was evening part time. So, to avoid babysitters and daycare, they would trade me and my brother in the lab," Steven says. 

Though he considered going into pharmacy work, ultimately his love of “how complex things were” and some of the “cool instruments” he saw pushed him toward laboratory work. “At the end of the day, whatever that analyzer was doing, it was helping somebody—and that's what really stuck with me,” Steven says. 

Three careers, three memorable patient stories 

Although laboratory professionals often work out of public view, all three of them recall a specific patient they were able to help whose case left a lasting impression.  

Steven’s rare blood discovery 

For Steven, the moment came when a patient’s tests were all “pan-reactive across the board” and “even the blood type was messed up.”  

When his coworker returned with the reference lab results asking if he’d heard of “anti-H,' he said, “My jaw dropped." The woman had an extremely rare blood type known as para-Bombay, so rare many people only ever learn about it in books. He said it left the whole laboratory “nerding out over this patient." 

Though she didn’t need a blood transfusion at that time, if she had, he said, she would have likely received O-negative, often referred to as the universal donor, though it’s not. “That blood probably would've killed her,” he says. 

The experience was a career defining moment. 

Roger's first notable diagnosis 

Roger’s memorable patient came when he was only two months out of college, new on the job and the only MT on in the middle of the night. "I'm doing the differential and all of a sudden I was startled. I was awake." 

Roger saw something unusual in the patient’s blood and immediately placed a call over to the ER to find out the patient’s race. He believed he was seeing sickle cells, representing a type of anemia that commonly affects Black people among others. 

The next morning, the pathologist confirmed that they were definitely sickle cells and added, “you made a good call.” 

The patient turned out to be a fifteen-year-old Black girl who was in the throes of her first sickle crisis. 

Lois's overnight emergency 

Lois’s memorable patient happened when she was working night on call at nine months’ pregnant.  

A call came in for a nine-year-old boy whose potassium was 1.7, which, she says “is not compatible with life." 

The treatment was to give the boy potassium every hour, which kept Lois stuck at the hospital. "I spent the whole night there," she says. Colleagues took pity on her and would call her each time the doctor took a sample, so she didn’t have to stay in his room the whole time. 

The boy’s potassium remained so low, the hospital ran out of the medication, and he was eventually put on a life flight to another hospital. 

"Long story short, he was an undiagnosed diabetic," she says. The boy lived in a rural part of the county where healthcare was difficult to access. Though she didn’t learn of his fate, she felt hopeful that she played a key part in getting the boy necessary care. 

A worthy trade off 

Perhaps precisely because laboratory medicine remains underrecognized and often misunderstood, the trio firmly believe in the value of the work. They’ve loved their careers, which has brought meaningful work, intellectual challenges, and the opportunity to improve lives every day. 

Though they missed a lot of holidays and family events over the years due to their jobs, Roger says he wouldn’t trade his career. “We knew that we were there helping people and that made the job worthwhile," he says. 

Steven agrees that while their jobs “might not be front-page news,” it’s rewarding. “You know you’ve made a difference,” he says. 

 For more Roots + Routes stories, click here.